Noticias

Noticias

  • Título: TriVascular Technologies (TRIV) IPO Opens Lower
  • Fecha: 15-04-2014

  • The IPO for TriVascular Technologies, Inc. (Nasdaq: TRIV) opened for trading at $11.35 after pricing 6,500,000 shares of its common stock at a public offering price of $12.00 per share, below the expected $12-$15 range. Shares have since recovered some of the losses; last trading at $11.80, down 1.7%.

    J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated are acting as co-managers. TriVascular has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the same price.

    TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Prime Abdominal Stent Graft System, the lowest profile FDA-approved system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.



  • Fuente: endovascular.es